I think it makes some interesting points like regulators will have to change the current strain selection or the potential forecast for 27 and 28
https://www.pharmavoice.com/news/moderna-mrna-flu-vax-fda-nod-blockbuster-hurdles/827961/
I have just wanted to be extra careful with the title to not give a heart attack to anyone... I think It is a very interesting article...
Reddit is deleting the post so please Google the following:
mRNA Flu Vaccine Faces FDA Verdict: Approval Alone Won't Mean Coverage for Seniors
Nothing new but it is always good having science in your side :)
I think it is very interesting, these findings could push even further the narrative of mrna flu vaccine superiority
Edited: I previously said that don't have any relation with moderna and moderna was the main sponsor apologies for the mistake
Fresh from the oven...
Not sure about how important these news could be for moderna but I didn't see coming....
https://www.nytimes.com/2026/06/02/us/politics/rubio-kennedy-vaccines-gavi.html
But Mr. Rubio suggested in pointed testimony that he was reclaiming control of the U.S. relationship with Gavi, which has historically been managed by the State Department.
The State Department is “going to re-engage on the issue of Gavi,” Mr. Rubio told the Senate Foreign Relations Committee. He said that the department was not going to “yank” the matter from Mr. Kennedy, a longtime vaccine skeptic, or ignore “his points of view.” But he said that a few weeks ago, he had made the decision to resume management of the relationship.
CEPI will invest in a portfolio of candidates under development from longstanding partners with proven capabilities. These include candidates developed by IAVI; Moderna; and the University of Oxford, which will be manufactured at the Serum Institute of India (SII).
https://cepi.net/cepi-fast-tracks-three-bundibugyo-ebolavirus-vaccine-candidates
Under the agreement, CEPI has committed up to US $50 million to support preclinical development and Phase 1 clinical testing of Moderna's investigational BDBV vaccine candidate. The funding will also support parallel manufacturing activities, enabling doses to be produced while clinical evaluation is underway and positioning the program to rapidly advance into large-scale Phase 2/3 trials should the Phase 1 safety and immunogenicity data support further development.
Nothing new but very Interesting information....
The firm cited the company’s Phase III INT adjuvant melanoma interim analysis as a major catalyst for 2026. Moderna has guided the interim analysis to occur in 2026, with UBS estimating a potential timeframe around October or November.
UBS assigned a probability of success above 50% for the interim analysis. The firm noted the stock could move 25% to 50% higher if the interim analysis meets its endpoint.
The firm acknowledged a scenario where the study does not stop for interim analysis and would require waiting for the final analysis. UBS stated this could occur if more time is needed for the survival curves to separate.
Nothing new... But as always data supports the vaccine.
https://www.cidrap.umn.edu/covid-19/pfizer-moderna-covid-vaccines-70-76-effective-against-severe-illness-kids-2022-data#:\~:text=The%20adjusted%20vaccine%20effectiveness%20(VE,from%20Chang%20Gung%20University%20estimated
He was not fired... In the BOFA meeting they just asked If this can affect the pdufa approval of the flu vaccine...
Moderna says that we are on track for the approval.
https://www.nytimes.com/2026/05/12/us/politics/trump-fires-fda-commissioner-makary.html